Some animal models developed by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) and the Catalan Institute of Oncology (ICO) have served to validate the effectiveness of a new drug against ovarian cancer resistant to cisplatin. The multidisciplinary work, done in collaboration with the biopharmaceutical company Pharmamar, was published in the journal Clinical Cancer Research. The human tumor tissue is implanted in the same nude mouse organ from which it came...
More...
More...